Medical Innovation Exchange

FDA’s Califf backs limited use of single-arm trials, but says regulatory pathways for some cancers should 'move into a new phase'


Leave a Comment

Your email address will not be published.

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.